LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway

Kun Qiao¹, Shipeng Ning¹, Lin Wan¹, Hao Wu¹, Qin Wang¹, Xingda Zhang¹, Shouping Xu¹* and Da Pang¹,²*

Abstract

Background: An increasing number of studies have shown that long noncoding RNAs (lncRNAs) play essential roles in tumor initiation and progression. LncRNAs act as tumor promoters or suppressors by targeting specific genes via epigenetic modifications and competing endogenous RNA (ceRNA) mechanisms. In this study, we explored the function and detailed mechanisms of long intergenic nonprotein coding RNA 673 (LINC00673) in breast cancer progression.

Methods: Quantitative real-time PCR (qRT-PCR) was used to examine the expression of LINC00673 in breast cancer tissues and in adjacent normal tissues. Gain-of-function and loss-of function experiments were conducted to investigate the biological functions of LINC00673 in vitro and in vivo. We also explored the potential role of LINC00673 as a therapeutic target using antisense oligonucleotide (ASO) in vivo. RNA sequencing (RNA-seq), dual-luciferase reporter assays, chromatin immunoprecipitation (ChIP) assay, and rescue experiments were performed to uncover the detailed mechanism of LINC00673 in promoting breast cancer progression.

Results: In the present study, LINC00673 displayed a trend of remarkably increased expression in breast cancer tissues and was associated with poor prognosis in breast cancer patients. Importantly, LINC00673 depletion inhibited breast cancer cell proliferation by inhibiting the cell cycle and increasing apoptosis. Furthermore, ASO therapy targeting LINC00673 substantially suppressed breast cancer cell proliferation in vivo. Mechanistically, LINC00673 was found to act as a ceRNA by sponging miR-515-5p to regulate MARK4 expression, thus inhibiting the Hippo signaling pathway. Finally, ChIP assay showed that the transcription factor Yin Yang 1 (YY1) could bind to the LINC00673 promoter and increase its transcription in cis.

Conclusions: YY1-activated LINC00673 may exert an oncogenic function by acting as a sponge for miR-515-5p to upregulate the MARK4 and then inhibit Hippo signaling pathway, and may serve as a potential therapeutic target.

Keywords: YY1, LINC00673, miR-515-5p, MARK4, Hippo signaling pathway, Cell proliferation, Breast cancer

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death among women [1]. Despite marked improvements in diagnosis and treatment, breast cancer remains a dangerous disease among women globally [2]. Early detection is still of the utmost importance in reducing breast cancer mortality but is hampered by a lack of effective diagnostic biomarkers. Thus, it is necessary to elucidate the molecular mechanisms of breast cancer to improve its diagnosis and to provide tailored molecularly stratified therapy.

Long noncoding RNAs (lncRNAs) are defined as transcripts longer than 200 nucleotides that lack an extended open reading frame and thus do not code for proteins [3-5]. LncRNA expression is usually tissue-restricted and developmentally regulated and can change under specific pathological conditions. Indeed, several lncRNAs have been shown to influence behaviors in human cancers, such as uncontrolled proliferation, as well as metastasis formation, and it has been suggested that lncRNAs can act as oncogenes or tumor suppressors by interfering with different signaling pathways [6, 7]. Mechanistically, lncRNAs may influence the function of transcriptional complexes, modulate chromatin structures by serving as scaffolds between proteins, or act as microRNA sponges [4, 8]. Long intergenic nonprotein coding RNA 673 (LINC00673) was first annotated as a long intergenic noncoding RNA (lincRNA) on chromosome 17q24.3 [9]. Recent studies have reported that LINC00673 is a potential tumor suppressor whose germline variation is associated with pancreatic cancer risk [10]. Conversely, LINC00673 was identified to play a role in tumorigenesis in a variety of malignancies [11-15]. A rapidly growing number of studies have suggested that cytoplasmic lncRNAs are essential mediators of intracellular signaling pathways and are involved in regulating mRNA stabilization and transport as well as microRNA sponging [16-18]. Although LINC00673 has been implicated in the regulation of breast cancer cell metastasis via the modulation of epithelial-mesenchymal transition (EMT) in breast cancer [19], it remains to be seen whether LINC00673 acts as a competing endogenous RNA (ceRNA) to promote cell proliferation in breast cancer.

The Hippo signaling pathway, a critical pathway in tumorigenesis, is evolutionarily conserved and has multiple biological functions in development, homeostasis, and the regeneration of tissues and organs [20]. The dysregulation of the Hippo signaling pathway occurs in many human tumors, including glioma, colorectal cancer, and breast cancer [21]. The major effectors of this pathway are the related transcriptional coactivators, Yes-associated protein 1 (YAP) and Transcriptional coactivator with PDZ-binding motif (TAZ), which, in association with various transcription factors such as transcriptional enhanced associate domains (TEADs), induce a growth-promoting gene expression program to regulate cell proliferation, apoptosis, and differentiation [22-24].

Antisense oligonucleotides (ASOs) are short, single-stranded, synthetic analogues of natural nucleic acids designed to specifically bind to a target messenger RNA (mRNA) in a sequence-specific manner through the Watson–Crick base-pair interactions [25]. They were first discovered to influence RNA processing and modulate protein expression over two decades ago [26-28]. Furthermore, ASOs can be designed to target genes associated with disease pathogenesis, including cancer, especially those that are not amenable to small-molecule or antibody inhibition [29–31]. With the rapid development of improved next-generation ASOs toward clinical application, a large amount of work is currently being carried out to develop chemical modifications and vehicles that will improve ASOs delivery and target engagement.

In the current study, we showed that LINC00673 was upregulated in breast cancer tissues compared with adjacent normal tissues and that elevated LINC00673 levels were associated with poor prognosis in breast cancer patients. Moreover, the knockdown of LINC00673 significantly inhibited breast cancer cell proliferation in vitro and in vivo. Furthermore, our study verified that antisense oligonucleotide therapy targeting LINC00673 substantially suppressed breast cancer progression in vivo. Mechanistically, LINC00673 promotes tumor proliferation by sponging miR-515-5p to regulate MARK4 and then inhibits the Hippo signaling pathway. Finally, we determined that the transcription factor Yin Yang 1 (YY1) could activate LINC00673 transcription in breast cancer cells. In conclusion, our study provides new information for breast cancer therapy, and LINC00673 may be a potential therapeutic target in breast cancer.

Methods

Patients and specimens
Breast cancer specimens and adjacent noncancerous tissues were obtained from Harbin Medical University Cancer Hospital, and patients with a histological diagnosis of breast cancer who had received neither chemotherapy nor radiotherapy before surgical resection were recruited for the present study between 2010 and 2014. This study conformed to clinical research guidelines and was approved by the research ethics committee of Harbin Medical University Cancer Hospital. We obtained written informed consent from all patients.

Cell culture and treatments
Normal mammary cells (MCF-10A), breast cancer cell lines (MDA-MB-231, MDA-MB-453, MDA-MB-468,
Hs-578 T, MCF-7, T-47D and BT-549) and the 293 T cell line were obtained from the Chinese Academy of Sciences Cell Bank and Cellbio (China) and were cultured according to the suppliers’ instructions.

**RNA isolation and quantitative real-time PCR (qRT-PCR)**

Total RNA was extracted using Trizol Reagent (Invitrogen, CA, USA) according to the manufacturer’s instructions. First-strand complementary DNA (cDNA) was prepared with a Transcriptor First Strand cDNA Synthesis Kit (Cat# 04897030001, Roche, USA). Real-time PCR was performed using FastStart Universal SYBR Green Master (ROX) (Cat#04913914001, Roche) on a 7500 Fast Real-Time PCR system (ABI, USA). For the quantification of gene expression, we used the 2\(^{-\Delta\Delta Ct}\) method. GAPDH or U6 expression was used for normalization. The primer sequences were synthesized by Genepharma (Shanghai, China). All the primer sequences are available in Additional file 3: Table S1.

**Subcellular fractionation**

Nuclear/cytoplasmic fractionation was performed by using NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Cat#78835, Thermo Fisher) according to the manufacturer’s protocols. U1 was used as a nuclear control, while GAPDH was used a cytoplasmic control.

**Antisense oligonucleotide (ASO) and cell transfection**

ASO was designed and synthesized by Integrated DNA Technologies (Cat#257249069, USA). To determine the in vitro ASO interference efficiency, cells were seeded in six-well plates and transfected with 1.4 μg of the ASO premixed with 5.6 μl of DOTAP Liposomal Transfection Reagent (Cat#1120375001, Roche, USA). For the in vitro ASO proliferation assay, cells were seeded in 96-well plates and transfected with 5 μM of the ASO premixed with 1.0 μl DOTAP Liposomal Transfection Reagent. A total concentration of 0 μM of the ASO was used as the control. Lentiviruses expressing YY1, LINC00673 and sh-LINC00673 and controls were constructed by Genechem (Shanghai, China). Concentrated viruses were used to infect 5 × 10⁵ cells in a 6-well plate with 4–6 μg/ml Polybrene. The infected cells were then subjected to selection with 1 μg/ml puromycin (Cat#540411, Calbiochem, USA) for 1 week. Stable overexpression cell lines or knockdown cell lines were identified using qRT-PCR or western blotting. Small interfering RNA (siRNA) duplex oligonucleotides targeting human MARK4 and LINC00673 and controls were synthesized by Genechem (Shanghai, China). The miR-515-5p mimic and inhibitor were purchased from Ribobio (Guangzhou, China). Cell transfections were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. At 48 h post transfection, cells were harvested for qRT-PCR or western blot analyses. The ASO, shRNA and siRNA sequences are listed in Additional file 3: Table S1.

**Cell proliferation assays**

The CCK-8 assay and the colony formation assay were performed to test cell proliferation. Briefly, for the CCK-8 assay, 1 × 10³ cells were cultured in a 96-well plate at 37°C. After 10 μl CCK-8 solution was added to each well, plates were incubated at 37°C for 1 h. The cell proliferation curves were plotted by measuring the 450 nm absorbance at each indicated time point. Experiments were performed in triplicate. For the colony formation assay, cells were exposed to the indicated treatments, were seeded in 6-well plates and were cultured for 2 weeks. Cell colonies were washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde, stained with 0.1% crystal violet and imaged using an optical microscope.

**TUNEL assay and flow cytometry**

To detect apoptosis in sections of tumor tissues, a TUNEL assay was performed according to the manufacturer’s instructions (Cat#11684795910, Roche), as previously described [32]. Apoptosis was further examined using a FITC Annexin V Apoptosis Detection Kit I (BD Biosciences). Briefly, cells were harvested and washed twice with ice-cold PBS and were stained with PE Annexin V and 7-AAD (BD Biosciences, San Jose, CA, USA) for 15 min at room temperature. For the analysis of the cell cycle, the transfected cells were stained and fixed in ice-cold 75% ethanol overnight at 4°C. After fixation, the cells were washed and resuspended twice in PBS and were then incubated with propidium iodide (BD Bioscience) and RNase for 30 min at room temperature. The cells were then analyzed using a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA).

**Hematoxylin-eosin (H&E) staining**

Organs were fixed in 4% paraformaldehyde at 4°C overnight. Then, the tissues were embedded in paraffin and cut into 5-μm slices. Deparaffinized and rehydrated sections were stained with H&E. Then, the stained sections were observed under a microscope (Olympus, Tokyo, Japan).

**Western blotting and antibodies**

Cells were lysed with RIPA extraction reagent (Beyotime) supplemented with a protease inhibitor cocktail (Roche). Proteins were separated by 6–15% SDS-PAGE, transferred to 0.22 mm polyvinylidene fluoride membranes (Millipore), and then incubated with
antibodies. The bands on the blots were captured by using an Odyssey Infrared Imaging System (LI-COR Biosciences) and were quantified with Odyssey v1.2 software (LI-COR Biosciences). GAPDH and Tubulin were used as the internal controls. Antibodies against the following proteins were used: Bax (Cell Signaling Technology Cat#5023,1:1000), Bcl-2 (Cell Signaling Technology Cat#4223,1:1000), MARK4 (Cell Signaling Technology Cat#4834,1:1000), YY1 (Cell Signaling Technology Cat#46395,1:1000), phspho-YAP/TAZ sampler kit (Cell Signaling Technology Cat#52420), Cyclin D1 (Cell Signaling Technology Cat#2978,1:1000), GAPDH (Cell Signaling Technology Cat#5174, 1:1000), and Tubulin (Santa Cruz Biotechnology Cat#sc-73,242,1:1000). Alexa Fluor® 800 goat anti-mouse (LI-COR Biosciences, Cat#926–32,210,1:10000) or anti-rabbit (LI-COR Biosciences, Cat#926–32,211,1: 10000) was used as a secondary antibody. Protein bands were quantified using Odyssey v1.2 software (LI-COR Biosciences), and GAPDH and Tubulin were used as the internal controls.

Animal experiments
The animal study protocol was approved by the Institutional Animal Care and Use Committee of Harbin Medical University Cancer Hospital and was performed in accordance with the Guide for the Care and Use of Beijing Vital River Laboratory Animal Technology Co, Ltd. (Beijing, China). Mouse xenograft models were established using 4-week-old BALB/c nude female mice. MDA-MB-231 cells labeled with luciferase (1 × 10⁶; established using 4-week-old BALB/c nude female mice. Ltd. (Beijing, China). Mouse xenograft models were performed on the BGISEQ-500 platform at the Beijing Genomics Institute (BGI, Shenzhen, China). Statistical analysis was performed, and differentially expressed genes (DEGs) were selected that met the criteria of a fold change ≥ 1.3 and P ≤ 0.05. RNA-seq data were deposited in the Gene Expression Omnibus (Accession no. GSE133331, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133331).

RNA sequencing (RNA-seq)
RNA preparation, library construction and sequencing were performed on the BGISEQ-500 platform at the Beijing Genomics Institute (BGI, Shenzhen, China). Statistical analysis was performed, and differentially expressed genes (DEGs) were selected that met the criteria of a fold change ≥ 1.3 and P ≤ 0.05. RNA-seq data were deposited in the Gene Expression Omnibus (Accession no. GSE133331, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133331).

Bioinformatics analysis
The Cancer Genome Atlas (TCGA) (https://tcga-data.nci.nih.gov) and the MiTranscriptome (http://www.mitranscriptome.org) [33] breast cancer databases were used to compare the expression of LINC00673 in normal and breast cancer tissues by using R software. The LncBook (https://bigd.big.ac.cn/lncbook) [34] and TargetScan (https://www.targetscan.org/) [35] databases were used to examine putative miRNA interactions between LINC00673 and MARK4. The YY1 binding motif in the promoter region of LINC00673 was identified by JASPAR (http://jaspar.genereg.net/) [36] and TRANSFAC (http://gene-regulation.com/).

Statistical analysis
Student’s t-tests were used for comparisons between experimental and control conditions, and one-way ANOVA was used for multiple group comparisons. The Chi-square test was used to assess correlations between
LINC00673 expression and the clinicopathological features of breast cancer patients. The correlation between LINC00673 and MARK4 expression was analyzed using Spearman’s correlation test. The survival curves were constructed with the Kaplan-Meier method and were compared with the log-rank test. Statistical analysis was performed using GraphPad Prism 7. The results are expressed as the mean ± the standard deviation (SD) of at least three independent experiments. $P < 0.05$ was considered statistically significant.

**Results**

**LINC00673 is upregulated in breast cancer tissues and cell lines**

To investigate the expression of LINC00673 in breast cancer, the MiTranscriptome database was applied, and LINC00673 was expressed at higher levels in breast cancer samples than in normal breast tissues (Additional file 1: Figure S1a). This finding was further validated by TCGA breast cancer data showing that LINC00673 was upregulated in breast cancer tissues compared to normal tissues (Additional file 1: Figure S1b). To further validate this result, we investigated LINC00673 expression in 80 pairs of primary breast cancer tissues and their corresponding adjacent tissues. These results showed that LINC00673 expression was markedly increased in tumor tissues compared with normal tissues (Fig. 1a). When stratified by the median expression of LINC00673, patients with high LINC00673 expression had significantly shorter overall survival (OS) than those with low LINC00673 expression (Fig. 1b). In addition, we examined the correlation of LINC00673 expression with patients’ clinicopathological characteristics in breast cancer. LINC00673 expression was positively correlated with tumor size ($P = 0.024$), and Ki67 status ($P = 0.019$). However, no significant association was found between LINC00673 expression and age, lymph node metastasis (LNM), tumor-node-metastasis (TNM) stages, Her-2 status, or ER/PR status (Table 1). Next, we investigated the expression of LINC00673 in breast cancer cell lines, which included MDA-MB-231, MDA-MB-453, MDA-MB-468, Hs-578 T, MCF-7, T-47D, BT-549 and Normal mammary cells MCF-10A. These results showed that the expression of LINC00673 was significantly upregulated in the more aggressive MDA-MB-453, MDA-MB-468 and MDA-MB-231 cell lines compared with MCF-10A cells (Fig. 1c). Therefore, we hypothesize that high expression of LINC00673 may be involved in tumor cell proliferation and may be an oncogene in breast cancer.

**LINC00673 promotes breast cancer cell proliferation in vitro**

To determine the biological functions of LINC00673 in breast cancer cells, siRNAs were designed to silence LINC00673 in MDA-MB-231 and MDA-MB-453 cell lines and lentiviruses were designed to express LINC00673 in the Hs-578 T cell line (Fig. 2a). First, we demonstrated that LINC00673 knockdown suppressed cell viability and colony formation in MDA-MB-231 and MDA-MB-453 cells (Fig. 2b and c), while LINC00673 overexpression had the opposite effects in breast cancer cells (Fig. 2d and e). Next, we found that the suppression of LINC00673 induced cell cycle arrest in the G0/G1 phase, with a reduction in the percentage of cells in S phase compared with that in control cells (Fig. 2f). Compared with the control cells, breast cancer cells with LINC00673 knockdown had significantly increased apoptosis rates (Fig. 2g). Moreover, the knockdown of LINC00673 enhanced bax expression and reduced bcl-2 and cyclin D1 levels in breast cancer cells, confirming that LINC00673 is involved in apoptosis and cell cycle progression (Fig. 2h).

![Fig. 1](https://example.com/fig1.png) LINC00673 is upregulated in breast cancer tissues and cell lines. a LINC00673 expression was determined by qRT-PCR in 80 paired breast cancer tissues and adjacent normal tissues. b Kaplan-Meier OS curves are illustrated based on the LINC00673 level. The median expression level was used as the cutoff. c Expression of LINC00673 was verified by qRT-PCR in breast cancer cell lines and normal cell lines. The data are presented as the mean ± the SD of three independent experiments. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$, ****$P < 0.0001$; and ns, not significant.
LINC00673 downregulation suppresses cell proliferation in vivo and is a potential therapeutic target of breast cancer

To investigate the effects of LINC00673 on breast cancer proliferation in vivo, we inoculated nude mice with MDA-MB-231 cells that stably expressed lentiviral sh-LINC00673 to suppress LINC00673 expression (Fig. 3a). Tumor xenografts with downregulated LINC00673 showed markedly reduced volumes and weights compared to control xenografts (Fig. 3b and c). More apoptosis was observed in cells with downregulated LINC000763 than in control cells (Fig. 3d). Additionally, bax expression was increased while bcl-2 and cyclin D1 expression were reduced in the cells with downregulated LINC000763 compared to that in the control cells (Fig. 3e). Here, we explored the potential role of LINC00673 as a therapeutic target using antisense oligonucleotide (ASO). We designed ASO and confirmed that it decreased LINC00673 expression (Fig. 3f), and the ASO significantly impaired the proliferation of MDA-MB-231 cells (Fig. 3g). To evaluate the efficacy of this anti-LINC00673 targeted therapy, we created a xenograft mouse model. During the treatment process, we observed that the tumor volume and weight were significantly reduced in ASO-treated mice compared with the tumor volume and weight in normal saline-treated control mice. More importantly, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) liposomal ASO treatment more effectively inhibited tumor progression than the free ASO treatment (Fig. 3h). An increased number of apoptotic cells (Fig. 3i), increased bax expression and decreased bcl-2 and cyclin D1 expression were observed in the liposomal ASO treatment group compared to the control group (Fig. 3j). Previous research suggested that ASO may cause toxicity in the liver or in other internal organs [37, 38]. TUNEL and H&E staining revealed mild cell apoptosis and necrosis in the organs, and the biochemical parameters were similar between the treatment and control groups, which suggests that the ASO toxicity was limited (Additional file 2: Figure S2). Together, these results suggested that LINC00673 significantly promoted tumor growth and that the liposomal delivery of an ASO targeted to LINC00673 has great potential as a novel antitumor therapeutic agent.

LINC00673 promotes breast cancer cell proliferation by modulating the MARK4 and Hippo signaling pathways

RNA sequencing was performed to investigate the potential molecular mechanism of LINC00673 in breast cancer progression. MARK4, a member of the microtubule affinity regulating kinase (MARK) family, has been reported to promote proliferation via the Hippo signaling pathway [39]. Sequencing revealed that MARK4 mRNA expression was significantly reduced in the MDA-MB-453 cells in which LINC00673 was downregulated by siRNA compared to that in control cells (Fig. 4a). We found that compared to control cells, breast cancer cells with LINC00673 knockdown had significantly reduced MARK4, YAP, and TAZ expression and increased YAP phosphorylation levels in the Hippo signaling pathway (Fig. 4b and c). Moreover, we found that MARK4 was significantly overexpressed in human breast cancer tissues with shorter OS (Fig. 4d and e), and a positive correlation was found between LINC00673 and MARK4 (Fig. 4f). The results of CCK-8 assays showed that cotransfection could partially rescue the Lv-LINC00673 elevated growth ability in Hs-578 T cells (Fig. 4g). In summary, we demonstrated that LINC00673 promotes breast cancer cell proliferation via the Hippo signaling pathway by regulating MARK4.

**Table 1** Correlation between LINC00673 expression and the clinicopathological features of breast cancer

| Characteristics | No. (n = 80) | LINC00673 expression | P-value |
|-----------------|-------------|----------------------|---------|
| Age             |             |                      |         |
| < 50            | 38          | Low (n = 40)         | 0.446   |
| ≥ 50            | 42          | High (n = 40)        |         |
| Tumor size      |             |                      |         |
| ≤ 2 cm          | 31          | Low (n = 20)         | 0.024*  |
| > 2 cm          | 49          | High (n = 19)        |         |
| LNM             |             |                      |         |
| Negative        | 27          | Low (n = 17)         | 0.097   |
| Positive        | 53          | High (n = 23)        |         |
| TNM stage       |             |                      |         |
| I-II            | 74          | Low (n = 39)         | 0.089   |
| III-IV          | 6           | High (n = 1)         |         |
| ER expression   |             |                      |         |
| Negative        | 29          | Low (n = 16)         | 0.485   |
| Positive        | 51          | High (n = 24)        |         |
| PR expression   |             |                      |         |
| Negative        | 45          | Low (n = 23)         | 0.648   |
| Positive        | 32          | High (n = 17)        |         |
| Her-2 expression|             |                      |         |
| Negative        | 44          | Low (n = 24)         | 0.368   |
| Positive        | 36          | High (n = 16)        |         |
| Ki67 expression |             |                      |         |
| ≤ 14%           | 28          | Low (n = 19)         | 0.019*  |
| > 14%           | 52          | High (n = 21)        |         |

LNM lymph node metastasis, *P < 0.05
LINC00673 regulates MARK4 expression by competing for miR-515-5p

Recent findings indicate that lncRNAs can exert their function in different compartments of the cell. Most of the lncRNAs that have been investigated thus far act in the nucleus by regulating gene expression [40]. However, lncRNAs also act as ceRNAs to regulate mRNA degradation and translation in the cytoplasm [41]. Thus, we first assessed the cellular localization of LINC00673 by measuring its expression in the nucleus and cytoplasm in MDA-MB-453 and MDA-MB-231 cells. As shown in Fig. 5a, LINC00673 was mainly found in the cytoplasm of breast cancer cells. Therefore, we examined whether LINC00673 might be involved in cross-talk with any miRNAs in breast cancer. We used both the LncBook (https://bigd.big.ac.cn/lncbook) and TargetScan (http://
Fig. 3 (See legend on next page.)
www.targetscan.org/) databases to search for miRNAs that could be closely associated with LINC00673 and MARK4, and together these databases identified 258 miRNAs that may act as targets of LINC00673 and MARK4. Most of these miRNAs have unknown functions, therefore, we selected 40 miRNAs that have been reported to be involved in numerous cancers for further study (Additional file 4: Table S2). Among these miRNAs, we verified that the expression of 18 miRNAs were significantly increased by the knockdown of LINC00673 (Fig. 5b and c). Simultaneously, we noticed that one of these candidate miRNAs, miR-515-5p, has been found to dramatically inhibit breast cancer cell proliferation and to control cancer cell migration through MARK4 regulation in breast cancer [42, 43]. Therefore, we examined whether LINC00673 could interact with LINC00673 downregulation suppresses cell proliferation in vivo and is a potential therapeutic target of breast cancer. a Knockdown of LINC00673 by shRNA in MDA-MB-231 cells was confirmed by qRT-PCR. b Luminescence images of subcutaneous tumors in xenograft mouse models bearing tumors generated from MDA-MB-231 cells that were stably transfected with sh-LINC00673 or sh-NC on days 7, 14 and 30 after tumor cell injection. c Tumor volume and weight in mice treated with sh-LINC00673 or sh-NC. Tumor volume was calculated every 5 days, n = 5. d The effect of LINC00673 knockdown on tumor cell apoptosis was determined by TUNEL staining. e Protein levels of Bax, Bcl-2 and CyclinD1 in tumor tissues after the knockdown of LINC00673, as analyzed by western blotting assays. f qRT-PCR analysis of the relative LINC00673 expression in MDA-MB-231 cells transfected with ASO-LINC00673 (5 μM). The 0 μM group was used as the control. g CCK-8 assay detection of cell viability in MDA-MB-231 cells. The concentration of ASO was 5 μM. The 0 μM group was used as the control. h Representative ASO treatment tumor images, volumes and weights in the three treatment groups, n = 5. i The effect of ASO treatment on tumor cell apoptosis was determined by TUNEL staining. j Expression of Bax, Bcl-2 and Cyclin D1 in the three treatment groups, as determined by western blotting. The data are presented as the mean ± the SD of three independent experiments. ** P < 0.01 and *** P < 0.001. Scale bar: 50 μm

Fig. 3 LINC00673 promotes breast cancer cell proliferation by modulating the MARK4 and Hippo signaling pathways. a Expression heatmap of significantly differentially expressed transcripts after the RNA transcriptome sequencing analysis following LINC00673 knockdown. The red color indicates genes that were upregulated compared with the control cells, and the blue color indicates genes that were downregulated compared with the control cells. b The expression of MARK4 after the knockdown of LINC00673 was measured by using qRT-PCR. c Western blotting analysis of MARK4, p-YAP, YAP and TAZ in the indicated cells. d The expression of MARK4 was determined by qRT-PCR in 80 paired breast cancer tissues and adjacent normal tissues. e Kaplan-Meier analyses of the correlations between MARK4 expression and OS in 80 breast cancer patients. f A positive correlation was confirmed between LINC00673 and MARK4 by Pearson correlation analysis. g Growth ability of Hs-578T cells after cotransfection with Lv-LINC00673, si-MARK4, as determined by CCK-8 assays. The data are presented as the mean ± the SD of three independent experiments. ** P < 0.01 and *** P < 0.001.
Fig. 5 (See legend on next page.)
miR-515-5p to regulate MARK4. We verified that the knockdown of LINC00673 negatively regulated miR-515-5p in both MDA-MB-231 and MDA-MB-453 cells (Fig. 5d). The upregulation and downregulation of miR-515-5p inversely affected LINC00673 expression (Fig. 5e). Then, we showed that miR-515-5p negatively regulated MARK4 mRNA and protein expression (Fig. 5f and g). We next explored whether miR-515-5p could directly bind to LINC00673 and MARK4. Dual-luciferase assays indicated that there was a significant reduction in luciferase activities after the cotransfection of miR-515-5p mimics and a wild-type LINC00673 or MARK4 reporter vector, but this reduction was not observed with the transfection of mutant LINC00673 and MARK4 reporter vectors (Fig. 5h). Finally, the treatment of MDA-MB-231 and MDA-MB-453 cells with si-LINC00673 and miR-515-5p inhibitors attenuated the reduction in MARK4, YAP and TAZ mRNA transcript levels caused by LINC00673 knockdown (Fig. 5i). Notably, the reduction in MARK4 and YAP/TAZ and the increase phosphorylated YAP protein expression was also abolished by miR-515-5p inhibitors in breast cancer cells transfected with si-LINC00673 (Fig. 5j). We next determined whether LINC00673 induced breast cancer cell proliferation through the miR-515-5p. The results of CCK-8 assays showed that the knockdown of LINC00673 expression dramatically reduced the proliferative capacity of breast cancer cells. As expected, in the cells cotransfected with si-LINC00673 and the miR-515-5p inhibitor, these effects were abolished (Fig. 5k). Similarly, the cotransfection of cells with Lv-LINC00673 and the miR-515-5p mimic attenuated the LINC00673-mediated increase in cell proliferation (Fig. 5l). In summary, these results showed that LINC00673 promoted tumor cell growth at least in part by acting as a ceRNA for miR-515-5p and thus regulating the MARK4/Hippo signaling pathways.

YY1 activates LINC00673 expression in breast cancer cells
To further examine the transcriptional regulation model of LINC00673 in breast cancer, we searched the TRAN SFAC (http://gene-regulation.com/) and JASPAR (http://jaspar.genereg.net/) databases to identify transcription factors that may regulate LINC00673. The transcription factor Yin Yang 1 (YY1) was predicted by both the TRAN SFAC and JASPAR data bases with high scores (Additional file 5: Table S3). The predicted binding sites of YY1 in the LINC00673 promoter sequence are illustrated in Fig. 6a. To explore whether LINC00673 is a downstream target of YY1, we knocked down YY1 by siRNA in MDA-MB-231 cells, which led to a significant decrease in LINC00673 expression (Fig. 6b and c). Furthermore, the overexpression of YY1 significantly elevated LINC00673 expression in MDA-MB-231 cells (Fig. 6d and e). Moreover, ChIP assays showed that the LINC00673 promoter was specifically pulled down by a YY1-specific antibody but not the control antibody (Fig. 6f). Taken together, these findings suggest that YY1 is a bona fide transcriptional activator of LINC00673.

Discussion
With the development of techniques for sequencing entire genomes, increasing number of molecular mechanisms in breast cancer have been described [44, 45]. LncRNAs have been shown to play important roles and to act through multiple mechanisms, including as ceRNAs, in a variety of cancers [46–48]. There is still some controversy regarding the role of LINC00673 in carcinogenesis, numerous studies have described LINC00673 as either a tumor suppressor or promoter [11–15]. Although previous studies have also identified the oncogenic role of LINC00673 was upregulation in breast cancer tissues and related with patients’ prognosis [19], very little is known about the molecular mechanisms of LINC00673 in breast cancer carcinogenesis. To this end, in the current study, we confirmed the oncogenic function of LINC00673, as it enhanced the proliferative capacity of breast cancer cells in a series of functional experiments both in vitro and in vivo. In addition, we demonstrated that LINC00673 expression was positively correlated with tumor size and Ki67 status. Of note, Xia E et al. reported that LINC00673 could influence B7-H6 expression to enhance cell
migration, invasion and epithelial-mesenchymal transition (EMT) in breast cancer [19]. However, no significant association was found between LINC00673 and lymph node metastasis (LNM), tumor-node-metastasis (TNM) stages in our study. Due to the randomness of clinical samples that may lead to different experimental results, the number of patients included in the validated cohort should be increased to provide more convincing results. Given the significant effects of LINC00673 on breast cancer progression, the mechanism related to LINC00673 urgently needs to be explored.

Here, we used RNA-seq to identify the regulatory networks of mRNAs and noncoding RNAs in breast cancer. Among the results from the analysis of potential mRNA interactions, MARK4 sparked our interest since it is associated with tumorigenesis [49, 50]. Previous studies showed that MARK4 attenuates the proliferation and migration of MDA-MB-231 cells via the Hippo signaling pathway [39]. The Hippo pathway plays a critical role in regulating multiple aspects of growth at both the cellular and organ levels [20]. The main factors in this pathway are YAP and TAZ, which associate with the TEAD family of transcription factors [51, 52]. When the Hippo pathway is activated, it limits tissue growth and cell proliferation by phosphorylating and inhibiting YAP/TAZ. On the contrary, once the Hippo pathway is deactivated, YAP/TAZ are dephosphorylated and translocate into the nucleus, where they bind to TEAD and enhance proliferation, restrain apoptosis, and promote the migration of cancer cells [20]. In our study, we observed that LINC00673 induced the expression of MARK4, which was accompanied by alterations in YAP phosphorylation and total YAP protein levels, showing that LINC00673 inhibits the Hippo signaling pathway.

Fig. 6 YY1 activates LINC00673 expression in breast cancer cells. a YY1 binding motif and the prediction of YY1 binding sites within the promoter region of LINC00673 provided by the JASPAR database. b The knockdown efficiency of YY1 in MDA-MB-231 cells was determined by qRT-PCR and western blotting. c qRT-PCR analysis of LINC00673 expression in MDA-MB-231 cells after transfection with YY1 siRNA and the negative control. d The overexpression efficiency of YY1 in MDA-MB-231 cells was determined by qRT-PCR and western blot analysis. e qRT-PCR analysis of LINC00673 expression in MDA-MB-231 cells after transfection with Lv-YY1 and the negative control. f qRT-PCR of the ChIP products validating the binding capacity of YY1 to the LINC00673 promoter. g The mechanism of the regulatory network and function of LINC00673. LINC00673 promoted proliferation, induced apoptosis in breast cancer cells which could be enhanced by YY1 and acted as a ceRNA for miR-515-5p to regulate MARK4 and inactivate the Hippo signaling pathway. The data are presented as the mean ± the SD of three independent experiments. ** $P < 0.01$ and *** $P < 0.001$. 
Moreover, we found that LINC00673 was predominantly distributed in the cytoplasm of the cell, indicating that it plays a role in posttranscriptional regulation. There is increasing evidence that lncRNAs can function as ceRNAs for miRNAs in cancer [53]. Thus, our investigations, such as luciferase activity assays and rescue experiments, further confirmed that LINC00673 functions as a ceRNA by binding miR-515-5p to regulate MARK4 and then inhibits the Hippo pathway. All of these results led us to propose the existence of a regulatory network in which miRNAs and lncRNAs interact with each other to coregulate the expression and function of MARK4.

As expected, ASO successfully inhibited the progression of breast cancer in vivo. Notably, intravenous treatment with liposomal ASO was much more efficient in limiting tumor growth than treatment with free ASO. Thus, the future development of lncRNAs as potential therapeutics in the breast cancer, as well as in other cancers, seems promising.

Conclusions
In all, we showed that LINC00673 is activated by YY1 and acts as a sponge for miR-515-5p, regulating MARK4, inactivating the Hippo signaling pathway, and resulting in tumor progression (Fig. 6g). More importantly, LINC00673 is a potential therapeutic target for treating breast cancer.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13046-019-1421-7.

Abbreviations
ASO: Antisense oligonucleotide; ceRNA: Competing endogenous RNA; ChIP: Chromatin immunoprecipitation; DOTAP: 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) cationic liposomes were used to deliver ASO-LINC00673.

Acknowledgments
The authors thank the study investigators and staff who participated in this study.

Authors’ contributions
DP and SPX contributed to the study design and supervision. KQ contributed to study design, RNA sequencing data and public data interpretation, manuscript draft. SPN, LW and HW contributed to molecular biology experiments. QW and XDZ performed in vivo experiments. All authors contributed to review and revision of the manuscript. All authors read and approved the final manuscript.
Funding
This work was supported by funding from the Project 110 of Harbin Medical University Cancer Hospital (Grant Number 1102017–02), the National Natural Science Foundation of China (Grant Number 18102523, 81827149), Outstanding Youth Project of Heilongjiang Provincial Natural Science Foundation (Grant Number YQ201914027), Wu Lien-teh Science Foundation of Harbin Medical University (Grant number WLD-QN1706), Distinguished Young Scholars of Harbin Medical University Cancer Hospital (Grant Number JQCN2018–03) and Yong Elite Training Foundation Grant of Harbin Medical University Cancer Hospital (Grant Number YJ2016–02), Innovation Foundation for Graduate Students of Harbin Medical University (Grant number YSJCQ2016-52HYD).

Availability of data and materials
The authors declare that the data supporting the findings of this study are available within the article and its supplementary information files.

Ethics approval and consent to participate
This study protocol conformed to clinical research guidelines and was approved by the research ethics committee of Harbin Medical University Cancer Hospital.

Consent for publication
Manuscript is approved by all authors for publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin 150086, China. 2Heilongjiang Academy of Medical Sciences, 157 Baojian Road, Harbin 150086, China.

Received: 13 August 2019 Accepted: 10 September 2019
Published online: 17 October 2019

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. CA Cancer J Clin. 2018;68:394–424.
2. Waks AG, Winer EP. Breast Cancer treatment: a review. JAMA. 2013;310:2053–64.
3. Jandura A, Krause HM. The new RNA world: growing evidence for Long non-coding RNAs in Cancer. Trends Mol Med. 2018;24:257–68.
4. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Integrative annotation of human long non-coding RNAs reveals global properties and specific subtypes. Genes Dev. 2011;25:1915–27.
5. Zheng L, Huang X, Tan W, Yu Q, Du Z, Chang J, et al. Pancreatic cancer risk variant in UNCG00673 creates a miR-1231 binding site and interferes with PTEN1 degradation. Nat Genet. 2016;48:747–57.
6. Guan H, Zhu T, Wu S, Liu S, Liu B, Wu J, et al. Long non-coding RNA LINC00673-v4 promotes aggressiveness of lung adenocarcinoma via activating WNT/b-catenin signaling. Proc Natl Acad Sci U S A. 2019;116:4019–29.
7. Zheng LG, Zhou XK, Zhou RJ, Lv HZ, Li WP. Long non-coding RNA LINC00673 promotes hepatocellular carcinoma progression and metastasis through negatively regulating miR-205. Am J Cancer Res. 2017;7:2536–46.
8. Wu L, Zhang H, Niu Y, Wu Y, Sun W, Li H, et al. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial-mesenchymal transition by sponging miR-150-5p. Mol Cancer. 2017;16:118.
9. Meng XF, Zhao LY, Chu XF. LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 2019;23:2075–83.
10. Huang M, Hou J, Wang Y, Xie M, Wei C, Nie F, et al. Long non-coding RNA LINC00673 is activated by SP1 and exerts oncogenic properties by interacting with LSD1 and EZH2 in gastric Cancer. Mol Ther. 2017;25:1014–26.
11. Rashid F, Shah A, Shan G. Long non-coding RNAs in the cytoplasm. Genomics Proteomics Bioinformatics. 2016;14:73–80.
12. Tichon A, Gil N, Lubelsky Y, Havin Solomon T, Lemze D, Itzkovitz S, et al. A conserved abundant cytoplasmic long non-coding RNA modulates repression by Pulmilo proteins in human cells. Nat Commun. 2016;7:12209.
13. Li Z, Cai B, Abdalla BA, Zhu X, Zheng M, Han P, et al. LncRNA-LIN1 controls muscle atrophy via sponging miR-15 family to activate IGFI-P1K/AKT pathway. J Cachexia Sarcopenia Muscle. 2019;10:391–410.
14. Xia E, Shen Y, Blandari A, Zhou X, Wang Y, Yang F, et al. Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating 87–H6 and epithelial-mesenchymal transition. Am J Cancer Res. 2018;8:1273–87.
15. Ma S, Meng Z, Chen R, Guan KL. The hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019;88:577–604.
16. Sanchez-Vega F, Mina M, Armanina J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the Cancer genome atlas. Cell. 2018;173:321–37 e10.
17. Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and Cancer. Cell. 2015;163:811–28.
18. Chang L, Azzolin L, Di Biagio D, Zanconato F, Battilana G, Lucon Xiccato R, et al. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature. 2018;563:265–9.
19. Yang XM, Cao XY, He P, Li J, Feng MX, Zhang YL, et al. Overexpression of Rac GT-Pase activating protein 1 contributes to proliferation of Cancer cells by reducing hippo signaling to promote cytokinesis. Gastroenterology. 2018;155:1233–49.
20. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 2012;33:1451–8.
21. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978;75:285–8.
22. Muntoni F, Wood MJ. Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov. 2011;10:621–31.
23. Opalinska JB, Gewirz AM. Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov. 2002;1:503–14.
24. Gleave ME, Monia BP. Antisense therapy for Cancer. Nat Cancer. 2005;6:468–79.
25. d’Ydewalle C, Ramos DM, Pyles NJ, Ng SY, Gorz M, Pilato CM, et al. The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy. Neurology. 2017;90:665–79.
26. Gutschner T, Hammerle M, Eismann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73:1180–9.
27. Xu S, Wang P, Zhang J, Wu H, Sun S, Zhang J, et al. Al-lncRNA EGT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer. Mol Cancer. 2019;18:89.
28. Iyer MK, Nilakhas Y, Malk R, Singhal U, Sahu A, Hosono Y, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47:199–208.
29. Ma L, Cao J, Liu L, Du Q, Li Z, Zou D, et al. LincBook: a curated knowledgebase of human long non-coding RNAs. Nucleic Acids Res. 2019;47:D128–D34.
30. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.
31. Khan A, Fomes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, van der Lee R, et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res. 2018;46:D260–D6.
32. Deckmann A, Hagedorn PH, Burki Y, Brügmann C, Berrera M, Ebeling M, et al. A sensitive in vitro approach to assess the hybridization-dependent toxic potential of high affinity Gapmer oligonucleotides. Molecular therapy Nucleic Acids. 2018;10:645–54.
33. Yu RZ, Grundy JS, Grady RS. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol. 2013;19:699–82.
34. Heidary Arash E, Shiban A, Song S, Attisano L. MARK4 inhibits hippo signaling to promote proliferation and migration of breast cancer cells. EMBO Rep. 2017;18:420–36.
40. Luo J, Wang K, Yeh S, Sun Y, Liang L, Xiao Y, et al. LncRNA-p21 alters the antitumor enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling. Nat Commun. 2019;10:2571.

41. Wang CJ, Zhu CC, Xu J, Wang M, Zhao WY, Liu Q, et al. The IncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs. Mol Cancer. 2019;18:115.

42. Pinho FG, Frampton AE, Nunes J, Krell J, Alshaker H, Jacob J, et al. Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation. Cancer Res. 2013;73:5936–48.

43. Pardo OE, Castellano L, Munro CE, Hu Y, Mauri F, Krell J, et al. miR-515-5p controls cancer cell migration through MARK4 regulation. EMBO Rep. 2016;17:570–84.

44. Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018;50:1705–15.

45. Li W, Zhang Z, Liu X, Cheng X, Zhang Y, Han X, et al. The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. J Clin Invest. 2017;127:3421–40.

46. Marchese FP, Raimondi I, Huang W, Smaldino PJ, Zhang Q, Miller LD, Cao P, Stadelman K, et al. Yin Yang 1 contains G-quadruplex structures in its promoter and 5′-UTR and its expression is modulated by G4 resolvase 1. Nucleic Acids Res. 2012;40:1033–42.

47. Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21:1253–61.

48. Wang CJ, Zhu CC, Xu J, Wang M, Zhang P, Yu Y, et al. The emerging function and mechanism of ceRNAs in Cancer. Trends Genet. 2016;32:211–24.

49. Magnani I, Novelli C, Fontana L, Tabano S, Rovina D, Moroni RF, et al. Differential signature of the centrosomal MARK4 isoforms in glioma. Anal Cell Pathol (Amst). 2011;34:319–38.

50. Sato S, Onomura D, Ueda Y, Dansako H, Honda M, Kaneko S, et al. Ribavirin-induced down-regulation of CCAAT/enhancer-binding protein α leads to suppression of lipogenesis. Biochem J. 2019;476:137–49.

51. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YY1-dependent gene induction and growth control. Genes Dev. 2008;22:1962–71.

52. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem. 2009;284:13355–62.

53. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? Cell. 2011;146:353–8.

54. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25:1125–42.

55. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and YY1-miR-29 regulatory circuitry in human colorectal cancer. Nat Commun. 2019;10:663.

56. Ratten DK, Corleone G, Györffy B, Perone Y, Staven N, Barozzi I, et al. Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nat Med. 2018;24:1469–80.

57. Huang W, Smaldino PJ, Zhang Q, Miller LD, Cao P, Stadelman K, et al. Yin Yang 1 contains G-quadruplex structures in its promoter and 5′-UTR and its expression is modulated by G4 resolvase 1. Nucleic Acids Res. 2012;40:1033–49.

58. Lee MH, Lahusen T, Wang RH, Xiao C, Xu X, Hwang YS, et al. Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation. Oncogene. 2012;31:116–27.

59. Liu Z, Sall A, Yang D. MicroRNA: an emerging therapeutic target and intervention tool. Int J Mol Sci. 2008;9:978–99.

60. Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017;16:89–100.

61. Lennox KA, Behlke MA. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res. 2016;44:863–77.

62. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11:1245–50.

63. Fox NG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J, et al. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature. 2016;534:407–11.

64. Xing Z, Lin A, Li C, Liang K, Wang S, Liu Y, et al. IncRNA directs cooperative epigenetic regulation downstream of chemokine signals. Cell. 2014;159:1110–25.

65. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–6.

66. Pakunlu RT, Wang Y, Saad M, Khandare JJ, Starooyvotov V, Minko T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release. 2006;114:153–62.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.